Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

• Status: Completed
• Trial end date: 2017-08-24
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical research study is to compare chemotherapy given with rituximab to chemotherapy followed by rituximab. The safety of both treatment schedules will be studied. Laboratory tests of genetic changes in blood and bone marrow before and during the study will also be monitored.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: Genentech, Inc.
• Treatments: Antibodies; BB 1101; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Doxorubicin; Etoposide; Etoposide phosphate; Fludarabine; Fludarabine phosphate; Immunoglobulins; Interferon alpha-2; Interferon-alpha; Interferons; Liposomal doxorubicin; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Mitoxantrone; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Prednisone; Procarbazine; Rituximab; Vidarabine; Vincristine

Criteria

Inclusion Criteria:

1. Previously untreated stage IV indolent B-cell lymphoma [Amendment May 2001:

eligibility restricted to follicular lymphoma]

2. Age <76

Exclusion Criteria:

N/A